NEWPATH MANAGEMENT, L.P.

Thesis

Newpath Management, L.P., operating as Newpath Partners, is a venture capital firm founded in 2018 and headquartered in Boston, Massachusetts. The firm's unique investment thesis centers on creating biotechnology companies from the ground up, in close partnership with leading academic scientists. Newpath focuses on identifying and nurturing breakthrough biology platforms with the potential to address significant unmet medical needs. Their core strategy involves building biotechnology companies, often before they formally exist, by partnering with academic researchers. They specialize in the life sciences and biotechnology sector, with a particular emphasis on gene editing technologies (prime editing, base editing, and epigenetic editing), regenerative medicine (cell therapy, tissue engineering, and regenerative approaches), drug discovery platforms (focusing on novel therapeutic modalities and discovery technologies), and breakthrough biology platforms (targeting emerging therapeutic approaches with high scientific novelty). The firm actively seeks companies with high scientific originality and the potential for groundbreaking treatments. Newpath typically invests in stages ranging from pre-seed to Series B and growth equity. They operate as a lead investor, frequently leading Series A rounds for companies they have helped form or guided from the seed stage. As of December 2021, their second fund, Fund II, closed at $350 million, with a stated goal of supporting the creation of 8-12 additional biotech companies. Their first fund, launched in 2018, had an initial offering of $125 million and sold $111.3 million. Newpath Partners III, L.P. had an offering amount of $350 million. The total gross asset value across three private funds is reported as $723.8 million. The firm's geographic scope is primarily the United States. Newpath Partners'

Related lists

• Pre-seed investors based in Boston, MA
• Seed investors based in Boston, MA
• Series A investors based in Boston, MA